PET/MRI imaging in neuroendocrine neoplasm

Virarkar, Mayur; Montanarella, Matthew; Itani, Malak; Calimano-Ramirez, Luis; Gopireddy, Dheeraj Reddy; Bhosale, Priya

doi:10.1007/s00261-022-03757-1

Cited by 3 publications

(3 citation statements)

References 72 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most publications comparing SSTR PET/CT with SSTR PET/MRI are performed by a same-day tracer injection with PET/CT preceding PET/MRI. 16 In our study, we defined PET union as the union of malignant lesions on PET CT and PET MRI , and used it as the reference standard for CT and MRI. There is a twofold reasoning for using PET union as the reference standard instead of PET CT and PET MRI separately.…”

Section: Discussionmentioning

confidence: 99%

“…15 However, the implementation of SSTR PET/ MRI in routine clinic for NETs and PRRTselection is currently hampered due to (i) heterogeneous literature about the choice of acquisition protocol for SSTR PET/MRI, (ii) lack of identification of NET-patients that would have a substantial added benefit of SSTR PET/MRI compared to SSTR PET/CT and (iii) ultimately lack of reimbursement for PET/MRI in several countries. 16 The primary aim of our study was to prospectively investigate whether CT or MRI with diffusion-weighted sequences, is the best hybrid partner for SSTR PET. The best hybrid partner was defined as the one with the highest concordance rate with PET, as double confirmation of lesions on two different imaging modalities strongly increases the likelihood that these lesions are malignant, avoiding the need for additional confirmation.…”

Section: Introductionmentioning

confidence: 99%

“…However, the implementation of SSTR PET/MRI in routine clinic for NETs and PRRT-selection is currently hampered due to (i) heterogeneous literature about the choice of acquisition protocol for SSTR PET/MRI, (ii) lack of identification of NET-patients that would have a substantial added benefit of SSTR PET/MRI compared to SSTR PET/CT and (iii) ultimately lack of reimbursement for PET/MRI in several countries. 16 …”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Intra-individual qualitative and quantitative comparison of [⁶⁸Ga]Ga-DOTATATE PET/CT and PET/MRI

Lens,

Ahmadi Bidakhvidi,

Vandecaveye

et al. 2023

Ther Adv Med Oncol

View full text Add to dashboard Cite

Background: Somatostatin receptor (SSTR) positron emission tomography (PET) is a cornerstone of neuroendocrine tumor (NET) management. Hybrid PET/magnetic resonance imaging (MRI) is now available for NET-imaging, next to PET/computed tomography (CT). Objectives: To determine whether CT or MRI is the best hybrid partner for [68Ga]Ga-DOTATATE PET. Design: Monocentric, prospective study. Methods: Patients received a same-day [68Ga]Ga-DOTATATE PET/CT and subsequent PET/MRI, for suspicion of NET, (re)staging or peptide receptor radionuclide therapy-selection. The union (PETunion) of malignant lesions detected on PETCT and PETMRI was the reference standard. Concordance of detection of malignant lesions in an organ was measured between PETunion and CT and PETunion and MRI. Seven bins were used to categorize the number of malignant lesions, containing following ordinal variables: 0, 1, 2–5, 6–10, 11–20, >20 countable and diffuse/uncountable. The difference in number of malignant lesions was obtained as the difference in bin level (‘Δbin’) between PETunion and CT and PETunion and MRI with a Δbin closer to zero implying a higher concordance rate. Results: Twenty-nine patients were included. Primary tumors included 17 gastroenteropancreatic-NETs, 1 colon neuroendocrine carcinoma, 7 lung-NETs and 2 meningiomas. Patient level concordance with PETunion was 96% for MRI and 67% for CT ( p = 0.039). Organ level concordance with PETunion was 74% for MRI and 40% for CT ( p < 0.0001). In bone, there was a higher concordance rate for MRI compared to CT, 92% and 33%, respectively ( p = 0.016). Overall, a mean Δbin of 0.5 ± 1.1 for PETunion/MRI and 1.4 ± 1.2 for PETunion/CT ( p < 0.0001) was noted. In liver, a mean Δbin of 0.0 ± 1.1 for PETunion/MRI and 1.7 ± 1.2 for PETunion/CT was observed ( p = 0.0078). In bone, a mean Δbin closer to zero was observed for PETunion/MRI compared to PETunion/CT, 0.6 ± 1.4 and 2.0 ± 1.5, respectively ( p = 0.0098). Conclusions: Compared to SSTR PET/CT, SSTR PET/MRI had a higher patient and organ level concordance for malignant tumoral involvement and number of malignant lesions, with a clear added value in bone and liver specifically.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Intra-individual qualitative and quantitative comparison of [⁶⁸Ga]Ga-DOTATATE PET/CT and PET/MRI

Lens,

Ahmadi Bidakhvidi,

Vandecaveye

et al. 2023

Ther Adv Med Oncol

View full text Add to dashboard Cite

show abstract

PET/MRI for evaluation of patients with pancreatic cancer

et al. 2023

View full text Add to dashboard Cite

Use of PET/CT in Neuroendocrine Tumors

Altun Tuzcu

2024

The Radiology of Cancer

View full text Add to dashboard Cite

Neuroendocrine tumours (NETs) are rare tumours arising from cells with a neuroendocrine phenotype dispersed through the body and characterised by the overexpression of somatostatin receptors. Because of this unique feature, functional imaging plays a crucial role in the diagnosis and management of NETs. Ga-68 labelled somatostatin analogue PET/CT has demonstrated better performance than somatostatin receptor scintigraphy. Although different somatostatin analogues labelled with 68 Ga were available; no significant difference was found between their efficiency. Ga-68 DOTA-PET/CT has many roles on treatment including "theranostic" approach in NET patients and has a potential to be used as the first step imaging method in these patients. However, 18 F-FDG PET/CT seems to be a more appropriate imaging method as the first choice for aggressive, poorly differentiated neuroendocrine cancers. In this book chapter, we aimed to discuss radiopharmaceuticals and current imaging methods used in neuroendocrine tumors in the light of the literature.

show abstract

PET/MRI imaging in neuroendocrine neoplasm

Cited by 3 publications

References 72 publications

Intra-individual qualitative and quantitative comparison of [⁶⁸Ga]Ga-DOTATATE PET/CT and PET/MRI

Intra-individual qualitative and quantitative comparison of [⁶⁸Ga]Ga-DOTATATE PET/CT and PET/MRI

PET/MRI for evaluation of patients with pancreatic cancer

Use of PET/CT in Neuroendocrine Tumors

Contact Info

Product

Resources

About

PET/MRI imaging in neuroendocrine neoplasm

Cited by 3 publications

References 72 publications

Intra-individual qualitative and quantitative comparison of [68Ga]Ga-DOTATATE PET/CT and PET/MRI

Intra-individual qualitative and quantitative comparison of [68Ga]Ga-DOTATATE PET/CT and PET/MRI

PET/MRI for evaluation of patients with pancreatic cancer

Use of PET/CT in Neuroendocrine Tumors

Contact Info

Product

Resources

About

Intra-individual qualitative and quantitative comparison of [⁶⁸Ga]Ga-DOTATATE PET/CT and PET/MRI

Intra-individual qualitative and quantitative comparison of [⁶⁸Ga]Ga-DOTATATE PET/CT and PET/MRI